Drugs that contain Axitinib

1. List of Inlyta drug patents

INLYTA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6534524 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Apr, 2025

(2 years from now)

US8791140 PF PRISM CV Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
Feb, 2035

(11 years from now)

US10869924 PF PRISM CV PD-L1 antagonist combination treatments
Jan, 2037

(13 years from now)

Market Authorisation Date: 27 January, 2012

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advan...

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's patent expiration?
More Information on Dosage

INLYTA family patents

18

United States

7

Japan

7

European Union

4

Spain

4

China

3

Mexico

3

Australia

3

Slovenia

3

Portugal

3

Korea, Republic of

3

Poland

3

Taiwan, Province of China

3

Canada

2

Israel

2

Denmark

2

Hong Kong

2

Russia

2

Hungary

2

Singapore

2

Brazil

2

Cyprus

2

New Zealand

1

South Africa

IB

1

IB

1

Turkey

1

Philippines

1

Argentina

1

Malaysia

EA

1

EA

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in